LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

SektorTervishoid

4.22 -3.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.21

Max

4.36

Põhinäitajad
By Trading Economics
Sissetulek	-23M -37M
Müük	-20M 21M
Aktsiakasum	-0.58
Kasumimarginaal	-177.011
Töötajad	293
EBITDA	-17M -32M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+44.52% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	100M 288M
Eelmine avamishind	7.43
Eelmine sulgemishind	4.22

Uudiste sentiment

By Acuity

12%

88%

11 / 344 Pingereas Healthcare

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. mai 2026, 22:47 UTC

Tulu

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28. mai 2026, 20:45 UTC

Tulu

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28. mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28. mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28. mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28. mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28. mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28. mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28. mai 2026, 22:37 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

M&A-Related Insurance Payments In North America Rise -- Market Talk

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28. mai 2026, 21:12 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28. mai 2026, 21:00 UTC

Tulu

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28. mai 2026, 20:57 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:55 UTC

Tulu

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28. mai 2026, 20:48 UTC

Kuumad aktsiad

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28. mai 2026, 20:34 UTC

Tulu

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28. mai 2026, 20:31 UTC

Tulu

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28. mai 2026, 20:28 UTC

Tulu

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28. mai 2026, 20:26 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Membership Fees $1.37B

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Net Sales $69.15B

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Same-Store Sales Up 9.8% >COST

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

44.52% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD 44.52%

Kõrge 9 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

11 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.